Analyst consensus rating
Passage Bio Analyst Rating: Buy
PASG is rated Buy by 2 analysts with a $15.50 target. As of 2026-08-23.
Direct answer
Passage Bio's consensus rating is Buy.
2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $15.50.
Forecast evidence checked August 23, 2026.
Get free Passage Bio email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $4.44
- Average price target
- $15.50
- High price target
- $23.00
- Low price target
- $8.00
- Low target gap
- +80.2%
- Target upside
- +249.1%
- High target gap
- +418%
- Target range width
- 337.8%
- Consensus rating
- Buy
- Analysts
- 2
- Evidence date
- August 23, 2026
- Valid through
- August 30, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Passage Bio?
Passage Bio has a verified Buy consensus. The same dataset has an average price target of $15.50.
How far are Passage Bio's low and high targets from the recorded price?
The low target implies +80.2%, while the high target implies +418%.
How many analysts are included in Passage Bio's consensus?
The verified consensus includes 2 analysts.
How is Passage Bio's target upside or downside calculated?
The average target of $15.50 is divided by the recorded price of $4.44, then one is subtracted to produce +249.1%. This does not guarantee a future return.
When was Passage Bio's analyst forecast verified?
The data was verified on 2026-08-23. The dataset is valid through 2026-08-30.